The fact that the less potent Cdk9.1260E shRNA was just as effective as the Cdk9.421E shRNA in producing an antitumor outcome yet produces less toxicity is consistent with the hypersensitivity of MYC-expressing HCC cells to Cdk9 inhibition (6). The gene discussed is CDK9; the disease is hepatocellular carcinoma.